Comparative efficacy of subcutaneous infliximab switching in remission and non-remission patients with inflammatory bowel disease after intravenous maintenance: 1-year outcome from a multicentre cohort study.

ABSTRACT:

Background

Elective switching from intravenous (IV) to subcutaneous (SC) infliximab (IFX) has shown efficacy in patients with inflammatory bowel disease (IBD). However, long-term outcomes for patients not in remission remain unclear.

Objectives

We evaluated the effectiveness of SC IFX switching in both remission and non-remission patients.

Design

This study was a retrospective multicentre study conducted across five tertiary hospitals in Korea.

Methods

Patients with IBD who switched to SC IFX between January 2021 and January 2023 were included. Clinical remission was defined as a Crohn's Disease Activity Index of <150 or a partial Mayo score of <2. Biochemical remission was defined as faecal calprotectin of <250 µg/g and C-reactive protein of <0.5 mg/dL. We inv

SUBMITTER: Bae JH 

PROVIDER: S-EPMC12035300 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature